Biolegend, 121405, PE anti-mouse CD103 Antibody, 25μg

CD103 is a type I transmembrane glycoprotein known as αE integrin or Integrin α IEL chain. It belongs to the integrin family and is primarily found on intestinal intraepithelial lymphocytes (IEL). CD103 is also expressed on a subpopulation of lamina propria T cells, epithelial dendritic cells, lamina propria-derived dendritic cells, and a small subset of peripheral lymphocytes. T regulatory cells express high level of CD103. The CD103 expression on lymphocytes can be induced upon activation and TGF-β stimulation. In association with integrin β 7 , CD103 is expressed as αE/β 7 heterodimer. Mature CD103 protein can be cleaved into 2 chains, a 150 kD (C-terminal) chain and a 25 kD (N-terminal) chain, which remain linked by disulfide bonds. CD103 binds to E-cadherin and mediates homing of lymphocytes to the intestinal epithelium.
25μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Armenian Hamster
Immunogen: Mouse intestinal intraepithelial lymphocytes
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining1,7 of acetone-fixed frozen sections, immunofluorescence2, and in vitro activation1.
Application References(PubMed link indicates BioLegend citation): LeFrancois L, et. al, 1994. Eur. J. Immunol. 24:635. (FC, IHC, IP) Mysorekar IU, et. al, 2002. J. Biol. Chem. 277:37811. (FC, IF) Mikami N, et al. 2011. J. Immunol. 186:6886. PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Quinn KM, et al. 2013. J. Immunol. 191:5085. PubMed Verhagen J and Wraith DC. 2014. J. Immunol. Methods. S0022. (FC) PubMed Xiao B, et al. 2015. PLoS One 1:e0115333. (IHC)
Product Citations: Parsons M, et al. 2014. J Immunol. 192:1361. PubMed Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed Bruand M, et al. 2021. Cell Reports. 36(3):109412. PubMed Ramakrishna C, et al. 2019. Nat Commun. 10:2153. PubMed Cheng K, et al. 2023. Small. 19:e2300125. PubMed Shi X, et al. 2023. iScience. 26:106143. PubMed Wang YC, et al. 2023. J Exp Med. 220:. PubMed Tang C, et al. 2023. Nat Commun. 14:1493. PubMed Latour YL, et al. 2023. Gut Microbes. 15:2192623. PubMed Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed Duraiswamy J, et al. 2021. Cancer Cell. 39:1623. PubMed Klaus T, et al. 2022. JCI Insight. 7: . PubMed Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed Lin YH 2023. Immunity. 56(1):207-223.e8. PubMed Tregoning JS, et al. 2023. Mol Ther Nucleic Acids. 31:29. PubMed Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed Kim S, et al. 2020. Immunity. 53(4):759-774.e9. PubMed Rezende R, et al. 2015. Nat Commun. 6: 8726. PubMed Vogel AJ et al. 2015. Frontiers in immunology. 0.477083333 . PubMed Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed Barry KC, et al. 2018. Nat Med. 24:1178. PubMed Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed Devalaraja S, et al. 2020. Cell. 1098:180. PubMed Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed Vereertbrugghen A, et al. 2021. Front Oncol. 11:598319. PubMed Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed Blankenhaus B, et al. 2014. PLoS Pathog. 10:1003913. PubMed Best SA, et al. 2018. Cell Metab. 27:935. PubMed Wang C, et al. 2021. Cell Rep. 37:110021. PubMed Hao F, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed Hartwig T et al. 2018. Cell reports. 25(13):3564-3572 . PubMed Stump CT, et al. 2021. Open Biol. 11:210245. PubMed Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed Ahadome S, et al. 2016. JCI Insight. 1:e87012. PubMed Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed Crooks SD, et al. 2022. Immunohorizons. 6:705. PubMed Van Braeckel-Budimir N, et al. 2018. Cell Rep. 24:3374. PubMed Murakami R, et al. 2013. PLoS One. 8:73270. PubMed Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed De Ponte Conti B, et al. 2021. Elife. 10:. PubMed Chandra J, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.83. PubMed Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed Beura LK, et al. 2018. Immunity. 48:327. PubMed Katagiri T, et al. 2019. Mucosal Immunol. 12:p1104. PubMed Tuong ZK, et al. 2021. iScience. 24:103326. PubMed Guo S, et al. 2021. Sci Rep. 11:23745. PubMed Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed Zhang XW, et al. 2021. Oncoimmunology. 10:1920739. PubMed Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed Keerthivasan S, et al. 2021. Immunity. 54(7):1511-1526.e8. PubMed Carlson PM, et al. 2021. J Immunol. 207:720. PubMed Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed Yamazaki S, et al. 2015. J Immunol. 195: 3427 - 3435. PubMed Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed Bonavita E, et al. 2020. Immunity. 1215:53. PubMed Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed Jin J, et al. 2020. Cell Reports. 30(12):4124-4136. PubMed Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed Lai NY, et al. 2020. Cell. 180:33:00. PubMed Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed Thomson CA, et al. 2018. J Immunol. 201:215. PubMed Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
RRID: AB_535948 (BioLegend Cat. No. 121405) AB_1133989 (BioLegend Cat. No. 121406)
Structure: Type I transmembrane glycoprotein, Integrin family, can be cleaved into 150 kD and 25 kD chains, associated with β7 integrin
Distribution: Majority of intestinal intraepithelial lymphocytes (IEL), subpopulation of lamina propria T cells, epithelial dendritic cells, small subset of peripheral lymphocytes, Treg cells.
Function: Retention and activation of CD103+ lymphocytes in the intestinal epithelium, regulate tissue-specific T cell homing.
Ligand/Receptor: E-Cadherin
Cell Type: Dendritic cells, Lymphocytes, T cells, Tregs
Biology Area: Immunology
Molecular Family: Adhesion Molecules, CD Molecules
Antigen References: 1. Kilshaw PJ and SJ. Murant. 1990. Eur. J. Immunol. 20:2201. 2. Karecla PI, et al. 1995. Eur. J. Immunol. 25:852. 3. LeFrancois L, et al. 1994. Eur. J. Immunol. 24:635. 4. Sung SS, et al. 2006. J. Immunol. 176:2161. 5. Johansson-Lindbom B, et al. 2005. J. Exp. Med. 202:1063. 6. Dujardin HC, et al. 2004. Proc. Natl. Acad. Sci. USA. 101:14473.
Gene ID: 16407
UniProt: View information about CD103 on UniProt.org
Clone: 2E7
Regulatory Status: RUO
Other Names: Integrin αIEL chain, Integrin αE chain, αE integrin, ITGAE
Isotype: Armenian Hamster IgG
Q: What type of PE do you use in your conjugates?
A: We use R-PE in our conjugates.